ARDS Drug Development Summit

Memo

The coronavirus pandemic has catapulted ARDS into the limelight and offered a once in a lifetime opportunity to meaningfully study large patient populations with homogenous disease – revolutionizing the notoriously challenging drug development landscape and widening the window of therapeutic opportunity to treat ARDS for the first time ever. From analyzing the molecular mechanisms behind COVID-19 related ARDS and assessing the robustness of available model systems to exploring the latest research on stem cell therapies, the inaugural ARDS Drug Development Summit is the premier platform for industry pioneers including Boehringer Ingelheim, Faron Pharmaceuticals and Alexion Pharmaceuticals to strategize against the drug development challenges faced in COVID-19/non-COVID-19 associated ARDS and catalyze a new wave of targeted therapies for pulmonary and systemic inflammation. Join 60+ inflammation, respiratory and virology experts across 3 unique days of focused discussion on the hottest ARDS research and leave with the actionable insights you need to supercharge your drug development and bring life-changing therapies through approval for ARDS patients around the world. Date and Time: On Tuesday July 13, 2021 at 7:55 am (ends Thursday July 15, 2021 at 3:00 pm) Prices: Conference + Workshops Day - Industry Pricing: USD 2697.00,Conference Only - Industry Pricing: USD 1999.00,Conference + Workshops Day - Academic Pricing: USD 2397.00,Conference Only - Academic Pricing: USD 1799.00 URLs: Tickets: https://go.evvnt.com/745323-0?pid=5569 Brochure: https://go.evvnt.com/745323-3?pid=5569 Speakers: Eric Jenkins, Senior Medical Director, Athersys, Melanie Kelly, Chief Scientific Officer, Tetra Biopharma, Nina Patel, Director, Clinical Development and Medical Affairs ILD, Boehringer Ingelheim, Shamsah Kazani, Senior Medical Director, Alexion Pharmaceuticals, Natacha Le Moan, Senior Director - Translational Research, Catalyst Biosciences, Tim Higenbottam, President, Faculty of Pharmaceutical Medicine, Brijesh Patel, Clinical Senior Lecturer in Cardiothoracic, Imperial College London, David Thickett, Professor of Respiratory Medicine, University of Birmingham, Pablo Pelegrin, Scientific Deputy Director and Principal Investigator, Biomedical Research Institute of Murcia, Joe Garcia, Chief Executive Officer, Aqua Lung Therapeutics, Kenneth Adler, Professor, Biomarck Pharmaceuticals, Jessie Huang, Post-Doctoral Associate, Boston University, Danny McAuley, Clinical Professor, Queens University Belfast, Juho Jalkanen, Vice President Business Development, Faron Pharmaceuticals, Seung-Yong Seong, Co-Chief Executive Officer, Shaperon, Miguel Forte, Chief Executive Officer, Bone Therapeutics, Anthony Ting, Vice President of Regenerative Medicine and Head of Cardiopulmonary Programs, Athersys, Bernhard Fischer, Chief Executive Officer, Apeptico, Marcelo Hill, Chief Scientific Officer, ARDAN Pharma